1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Patología Molecular del Cáncer

Patología Molecular del Cáncer

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alía EM, Matsumoto T, Vergote I, Colombo N, Mäenpää J, Lebreton C, de Gregorio N, Mosconi AM, Rubio-Pérez MJ, Bourgeois H, Fasching PA, Cecere SC, Hardy-Bessard AC, Denschlag D, de Percin S, Hanker L, Favier L, Bauerschlag D, Desauw C, Hillemanns P, Largillier R, Sehouli J, Grenier J, Pujade-Lauraine E, Ray-Coquard I.

    Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.

    Annals of oncology : official journal of the European Society for Medical Oncology . : .

    [doi:10.1016/j.annonc.2024.10.828]

  • Verlingue L, Italiano A, Prenen H, Guerra Alia EM, Tosi D, Perets R, Lugowska I, Moiseyenko V, Gumus M, Arslan C, Lindsay CR, Deva S, Taus Á, Oaknin A, Rottey S, Cicin I, Goksu SS, Smolin A, Roselló-Keränen S, Habigt C, Marbach D, Boetsch C, Dejardin D, Sleiman N, Evers S, Richard M, Ardeshir C, Charo J, Kraxner A, Teichgräber V, Keshelava N, Dziadziuszko R.

    Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma.

    EBioMedicine . 109: 105374-105374. Nº de citas: 1

    [doi:10.1016/j.ebiom.2024.105374]

  • Perez-Fidalgo JA, Gálvez-Montosa F, Guerra EM, Madariaga A, Manzano A, Martin-Lorente C, Rubio-Pérez MJ, Alarcón J, Barretina-Ginesta MP, Gaba L.

    SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023).

    CLINICAL & TRANSLATIONAL ONCOLOGY . 26(11): 2758-2770. Nº de citas: 2

    [doi:10.1007/s12094-024-03531-3]

  • Alonso-Gordoa T, Jimenez-Fonseca P, Martinez-Trufero J, Navarro M, Porras I, Rubió-Casadevall J, Arregui Valles M, Basté N, Hernando J, Iglesias Docampo L.

    SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023).

    CLINICAL & TRANSLATIONAL ONCOLOGY . 26(11): 2902-2916.

    [doi:10.1007/s12094-024-03736-6]

  • Carretero-Barrio I, Pijuan L, Illarramendi A, Curto D, López-Ríos F, Estébanez-Gallo Á, Castellvi J, Granados-Aparici S, Compañ-Quilis D, Noguera R, Esteban-Rodríguez I, Sánchez-Güerri I, Ramos-Guerra AD, Ortuño JE, Garrido P, Ledesma-Carbayo MJ, Benito A, Palacios J.

    Concordance in the estimation of tumor percentage in non-small cell lung cancer using digital pathology.

    SCIENTIFIC REPORTS . 14(1): 24163-24163.

    [doi:10.1038/s41598-024-75175-w]

  • Agudo-Quílez P, Martín-Moro F, Antoñana Ugalde S, Blanco-Peláez E, García-Cosío M, Tenelanda A, Lledó Navarro JL, López-Jiménez J, Zamorano Gómez JL.

    Primary Cardiac Aggressive B-Cell Lymphoma Affecting Right Ventricle and Acute Cardiovascular Events: Multidisciplinary Approach.

    Jacc. Case Reports . 29(19): 102562-102562.

    [doi:10.1016/j.jaccas.2024.102562]

  • Guerrero-Zotano Á, Pérez-García JM, Ruiz-Borrego M, Bermejo B, Gil-Gil M, de la Haba J, Alba Conejo E, Quiroga V, Carañana V, Urruticoechea A, Morales S, Bellet M, Antón A, Fernández-Abad M, Sánchez-Rovira P, Calabuig L, Pérez-Escuredo J, Sampayo-Cordero M, Cortés J, Llombart-Cussac A.

    Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score =18: DxCARTES study.

    ESMO open . 9(10): 103733-103733.

    [doi:10.1016/j.esmoop.2024.103733]

  • Alés-Martínez JE, Balmaña J, Sánchez-Rovira P, Salvador Bofill FJ, García Sáenz JÁ, Pimentel I, Morales S, Fernández-Abad M, Lahuerta Martínez A, Ferrer N, Zamora P, Bermejo B, Díaz-Redondo T, López-Ceballos MH, Galán M, Pérez-Escuredo J, Calabuig L, Sampayo M, Pérez-Garcia JM, Cortés J, Llombart-Cussac A.

    Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study.

    Breast . 77: 103780-103780.

    [doi:10.1016/j.breast.2024.103780]

  • Ruiz-Cánovas JM, Achote-Rea EA, Alonso-Gordoa T, Martínez-Lorca A, Araujo-Castro M.

    Metastatic pheochromocytoma: An unusual case and its multidisciplinary management.

    Hipertension y riesgo vascular . : .

    [doi:10.1016/j.hipert.2024.09.002]

  • Moreno-Moreno, Esther, Caniego-Casas, Tamara, Carretero-Barrio, Irene, Cortes, Alfonso, Muriel, Alfonso, Dominguez-Rullan, Jose Antonio, Martin-Gromaz, Carmen, Moreno-Bueno, Gema, Matias-Guiu, Xavier, Palacios, Jose, Perez-Mies, Belen.

    Histologic and Molecular Type Changes in Endometrial Cancer Recurrences in Comparison With Their Corresponding Primary Tumors.

    AMERICAN JOURNAL OF SURGICAL PATHOLOGY . 48(12): 1580-1587.

    [doi:10.1097/PAS.0000000000002308]

  • Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Xu L, Fairhurst RM, Khan S, Denduluri N, Rugo HS, Xu B, Pistilli B.

    Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.

    JOURNAL OF CLINICAL ONCOLOGY . : 2400920-2400920. Nº de citas: 1

    [doi:10.1200/JCO.24.00920]

  • Vaz Batista M, Pérez-García JM, Garrigós L, García-Sáenz JÁ, Cortez P, Racca F, Blanch S, Ruiz-Borrego M, Fernández-Ortega A, Fernández-Abad M, Iranzo V, Gion M, Martrat G, Alcalá-López D, Pérez-Escuredo J, Sampayo-Cordero M, Llombart-Cussac A, Braga S, Cortés J.

    The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis.

    Med (New York, N.Y.) . : 100502-100502. Nº de citas: 2

    [doi:10.1016/j.medj.2024.08.001]

  • Téllez L, Rincón D, Payancé A, Jaillais A, Lebray P, Rodríguez de Santiago E, Clemente A, Paradis V, Lefort B, Garrido-Lestache E, Prieto R, Iserin L, Tallegas M, Garrido E, Torres M, Muriel A, Perna C, Jesús Del Cerro M, d'Alteroche L, Rautou PE, Bañares R, Albillos A.

    Non-invasive assessment of severe liver fibrosis in patients with Fontan-associated liver disease: The VALDIG-EASL FONLIVER cohort.

    JOURNAL OF HEPATOLOGY . : .

    [doi:10.1016/j.jhep.2024.09.005]

  • Vaz Batista M, Pérez-García JM, Cortez P, Garrigós L, Fernández-Abad M, Gion M, Martínez-Bueno A, Saavedra C, Teruel I, Fernandez-Ortega A, Servitja S, Ruiz-Borrego M, de la Haba-Rodríguez J, Martrat G, Pérez-Escuredo J, Alcalá-López D, Sampayo-Cordero M, Braga S, Cortés J, Llombart-Cussac A.

    Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial.

    ESMO open . 9(9): 103699-103699. Nº de citas: 1

    [doi:10.1016/j.esmoop.2024.103699]

  • Niedra, Helvijs, Peculis, Raitis, Saksis, Rihards, Mandrika, Ilona, Vilisova, Sofija, Nazarovs, Jurijs, Breiksa, Austra, Gerina, Aija, Earl, Julie, Ruz-Caracuel, Ignacio, Rosas, Marta Gabriela, Pukitis, Aldis, Senterjakova, Natalja, Rovite, Vita.

    Tumor and a-SMA-expressing stromal cells in pancreatic neuroendocrine tumors have a distinct RNA profile depending on tumor grade

    MOLECULAR ONCOLOGY . : .

    [doi:10.1002/1878-0261.13727]

  • Ruz-Caracuel I, Caniego-Casas T, Alonso-Gordoa T, Carretero-Barrio I, Ariño-Palao C, Santón A, Rosas M, Pian H, Molina-Cerrillo J, Luengo P, Palacios J.

    Transcriptomic Differences in Medullary Thyroid Carcinoma According to Grade.

    ENDOCRINE PATHOLOGY . 35(3): 207-218. Nº de citas: 1

    [doi:10.1007/s12022-024-09817-0]

  • Gorospe L, Reguero-Callejas ME, Donate-Velasco I.

    Inflammatory Myofibroblastic Tumor of the Pleura With Lung Metastases in an Elderly Patient.

    ARCHIVOS DE BRONCONEUMOLOGIA . : .

    [doi:10.1016/j.arbres.2024.07.024]

  • González-Martínez S, Pérez-Mies B, Cortés J, Palacios J.

    Single-cell RNA sequencing in endometrial cancer: exploring the epithelial cells and the microenvironment landscape.

    Frontiers in immunology . 15: 1425212-1425212.

    [doi:10.3389/fimmu.2024.1425212]